Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population.
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyMass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular diseaseQuantitative and Selective Analysis of Feline Growth Related Proteins Using Parallel Reaction Monitoring High Resolution Mass SpectrometryThe role of insulin-like growth factor-1 in development of coronary no-reflow and severity of coronary artery disease in patients with acute myocardial infarctionThe trajectory of IGF-1 across age and duration of type 1 diabetesRole of insulin-like growth factor 1 in stent thrombosis under effective dual antiplatelet therapy.Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1Impact of insulin like growth factor-1 in development of coronary artery ectasiaParallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay.Reference Values for IGF-I Serum Concentrations: Comparison of Six ImmunoassaysRestricted nutrient intake does not alter serum-mediated measures of implant response in cell culture.Detecting growth hormone abuse in athletes.Analytical challenges in the detection of peptide hormones for anti-doping purposes.Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection.Translational mixed-effects PKPD modelling of recombinant human growth hormone - from hypophysectomized rat to patients.Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry.Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults.Disagreement in normative IGF-I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency.Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study.Validation of the IDS Octeia ELISA for the determination of insulin-like growth factor 1 in equine serum and tendon tissue extracts.IGF and IGFBP as an index for discrimination between vitamin D supplementation responders and nonresponders in overweight Saudi subjects.
P2860
Q26777682-3B0E4AE3-2237-4734-BF2F-3E7092036407Q28075372-0F02C998-4B54-4F95-8572-D7F608F5F0B7Q28554710-C5D7DE1D-DE7F-47C0-A449-5EC67C00E3F6Q33555475-1F4494F7-3AAD-4B20-97D5-5543445E11B8Q34536262-EE460A4B-3CB2-4663-AE09-E34E96A3A496Q34613424-707FB389-28BC-48F7-9A5F-7FDCB7863080Q35053898-F654A1C1-B4ED-4FAA-80AD-676EBCF01B5CQ35099857-45A22528-1B47-4ACA-8F41-D8A8C526A556Q35130223-123B5573-EC21-4567-8608-346B2E351571Q37318566-0B9571FA-3374-4F55-9B3D-E32996328B8DQ37401005-DEB773FD-A76A-445D-8B12-D5CFD142E979Q37876785-7ADF995C-7CDC-4790-A6F3-F1E863E1180DQ38029406-2E679C76-F9F3-4B47-BC74-6A064FA6ADF1Q38128225-1A8B4258-9053-4AF9-AAF0-4F6C3EDE17E2Q39963734-CD9EE776-2120-4501-8695-0E31806FFC20Q42324675-63EEDD6B-98AB-48AD-9EAB-154F541761FDQ42370216-7B8D1A91-CC40-4A0C-A3E6-9EC164C72925Q47865688-A1068FA0-C268-40C1-914B-57FD45C1DDEFQ50017693-9CEEC20E-2BD5-498B-A10F-12FF7C47FAA4Q51017255-5860881C-8799-4031-816F-58D62B42DF25Q55278764-9DDE7BD1-B4A9-4084-9E72-868037D0109E
P2860
Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Five commercially available in ...... th hormone treated population.
@en
Five commercially available insulin-like growth factor I
@nl
type
label
Five commercially available in ...... th hormone treated population.
@en
Five commercially available insulin-like growth factor I
@nl
prefLabel
Five commercially available in ...... th hormone treated population.
@en
Five commercially available insulin-like growth factor I
@nl
P2093
P2860
P356
P1476
Five commercially available in ...... th hormone treated population.
@en
P2093
Alexander Krebs
Elisabeth Spilcke-Liss
Georg Brabant
Henri Wallaschofski
Henry Völzke
Matthias Nauck
Thomas Kohlmann
P2860
P304
P356
10.1515/CCLM.2008.349
P577
2008-01-01T00:00:00Z